CORCEPT THERAPEUTICS INC Accounts Receivable, Allowance for Credit Loss, Recovery
CORCEPT THERAPEUTICS INC (CORT) reported Accounts Receivable, Allowance for Credit Loss, Recovery of $91.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › and Others
us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC accounts receivable, allowance for credit loss, recovery for fiscal 2025 was $91.67M, a 41.04% increase from fiscal 2024.
- CORCEPT THERAPEUTICS INC accounts receivable, allowance for credit loss, recovery for fiscal 2024 was $64.99M, a 43.90% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC accounts receivable, allowance for credit loss, recovery for fiscal 2023 was $45.17M, a 15.20% increase from fiscal 2022.
- CORCEPT THERAPEUTICS INC accounts receivable, allowance for credit loss, recovery for fiscal 2022 was $39.21M, a 24.95% increase from fiscal 2021.
| Period end | Accounts Receivable, Allowance for Credit Loss, Recovery 12 month |
|---|---|
| 2025-12-31 | $91.67M 10-K · filed 2026-02-24 |
| 2024-12-31 | $64.99M 10-K · filed 2026-02-24 |
| 2023-12-31 | $45.17M 10-K · filed 2026-02-24 |
| 2022-12-31 | $39.21M 10-K · filed 2025-02-26 |
| 2021-12-31 | $31.38M 10-K · filed 2024-02-15 |
| 2020-12-31 | $26.49M 10-K · filed 2023-02-28 |
| 2019-12-31 | $28.05M 10-K · filed 2022-02-15 |
| 2018-12-31 | $29.26M 10-K · filed 2021-02-23 |
| 2017-12-31 | $15.74M 10-K · filed 2020-02-24 |
| 2016-12-31 | $9.07M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |